Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2022 | The promise of elranatamab and other bispecifics in the treatment of myeloma

Karthik Ramasamy • 16 May 2022
COMy 2022
Multiple Myeloma Antibodies CAR-T Elranatamab

Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, shares some insights into the promise of bispecific antibodies, such as elranatamab, for the treatment of triple-class refractory myeloma patients. Dr Ramasamy highlights the promise that these agents have shown in clinical trials, and the importance of further investigating and better understanding how to manage the side effects of bispecific antibodies. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

More from Karthik Ramasamy

1:17
Novel agents to improve outcomes for patients with multiple myeloma in the salvage setting
Karthik Ramasamy • 20 Dec 2023
2:42
Optimizing maintenance therapy in multiple myeloma: an analysis from the PREAMBLE registry
Karthik Ramasamy • 20 Dec 2023
2:05
RADAR: guiding treatment for NDMM with MRD and genetic risk
Karthik Ramasamy • 20 Dec 2023
2:25
OxCOM: monitoring monoclonal gammopathies for progression to active myeloma
Karthik Ramasamy • 20 Dec 2023

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals